Abstract
CD44 expressed in monocytes and lymphocytes seems to play a crucial role in gastrointestinal inflammation, such as the one occurring in the context of inflammatory bowel diseases (IBD). Differentially methylated genes are distinctly expressed across monocyte subpopulations related to the state of Crohn's disease. Hence, the aim of this study was to detect CD44 expression at monocyte subpopulations, lymphocytes and granulocytes in relation to the type of IBD, therapy and disease duration. Monocyte subpopulations CD14++CD16−, CD14+CD16++ and CD14+CD16+, as well as other leukocytes, were analyzed for their CD44 expression using flow cytometry in 46 patients with IBD and 48 healthy controls. Patients with Crohn's disease treated with non-biological therapy (NBT) exhibited lower percentage of anti-inflammatory CD14+CD16++ monocytes, whereas NBT-treated patients with ulcerative colitis had lower expression of CD44 on CD14+CD44+ lymphocytes, in comparison to controls, respectively. Conversely, patients with Crohn's disease treated with biological therapy had higher percentage of CD44+ granulocytes, but lower expression of CD44 on anti-inflammatory monocytes compared to controls. Percentage of classical CD14++CD16- monocytes was lower in the <9 years of IBD duration subgroup, compared with the longer disease duration subgroup. The present study addresses the putative role of differentiation and regulation of monocyte and lymphocyte cells in tailoring IBD therapeutic regimes.
Biological therapy and surgery rates in inflammatory bowel diseases – Data analysis of almost 1000 patients from a Hungarian tertiary IBD center